Earnings release
Page 1
agenus NEWS RELEASE Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT + BAL in Neoadjuvant MSS Colon Cancer 2026-08-06 • Previously announced oversubscribed $ 85 million private placement , with up to an additional $ 255 million in potential proceeds from milestone - aligned warrants , supports ROBBIN execution • ROBBIN addresses approximately 38,000 newly diagnosed U.S. patients annually and an estimated annual U.S. sales opportunity of more than $ 7 billion ; initiation and first patient dosing are expected in the first quarter of 2027 • Previously reported NEST and UNICORN findings provided the direct clinical rationale for ROBBIN ; recent advanced - disease updates reinforce the durability of BOT + BAL activity • BOT + BAL access programs expanded across additional countries and treating institutions , contributing $ 6.4 million in second - quarter pre - commercial product revenue LEXINGTON , Mass .-- ( BUSINESS WIRE ) -- Agenus Inc. ( Nasdaq : AGEN ) , a leader in immuno - oncology innovation , today reported financial results for the second quarter ended June 30 , 2026 , and provided an update on its financing- supported strategy to advance botensilimab ( BOT ) , a multifunctional , Fc - enhanced anti - CTLA - 4 antibody , plus balstilimab ( BAL ) , an anti - PD - 1 antibody , in a curative - intent treatment setting before surgery in high - risk , resectable microsatellite - stable ( MSS ) colon cancer . As previously announced , Agenus completed an oversubscribed private placement in July 2026 structured to support ROBBIN , its planned global registrational Phase 3 trial of neoadjuvant ( before surgery ) BOT + BAL in patients with high - risk Stage II and Stage III microsatellite - stable ( MSS ) colon cancer . MSS disease accounts for approximately 85 % of early - stage colorectal cancers . In the population targeted by ROBBIN , treatment remains centered on surgery followed by chemotherapy or observation , with no new curative - intent therapies approved in more than 20 years.i , ii 1